Initial Results on Combination of Allurion Program With Low-dose GLP-1 Therapy

 Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.

52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass increased by 15% from 59.6% to 68.5%. All patients remained adherent to the GLP-1 medication through 8 months.

https://www.businesswire.com/news/home/20250320757662/en/Allurion-Announces-Initial-Results-on-the-Combination-of-the-Allurion-Program-With-Low-dose-GLP-1-Therapy-to-Optimize-Muscle-Mass-and-GLP-1-Adherence